PharmaShots | Incisive News in 3 Shots

Subscribe Now

All Posts by Date

PharmaShots Interview: Nanobiotix’s Laurent Levy Shares Insights on the P-III (NANORAY-312) Study of NBTXR3 for the Treatment of Head and Neck Squamous Cell Carcinoma

PharmaShots Interview: Nanobiotix’s Laurent Levy Shares Insights on the P-III (NANORAY-312) Study of NBTXR3 for the Treatment of H...

January 31, 2022

BMS’s Breyanzi (lisocabtagene maraleucel) Receive CHMP Positive Opinion for the Treatment of Multiple Indications

BMS’s Breyanzi (lisocabtagene maraleucel) Receive CHMP Positive Opinion for the Treatment of Multiple Indications

January 31, 2022

Regeneron & Sanofi’s Dupixent (dupilumab) Receive CHMP Positive Opinion for the Treatment of Severe Asthma

Regeneron & Sanofi’s Dupixent (dupilumab) Receive CHMP Positive Opinion for the Treatment of Severe Asthma

January 31, 2022

Akeso Reports First Patient Dosing in P-III Trial of Ivonescimab for the Treatment of Non-Squamous Non-Small Cell Lung Cancer

Akeso Reports First Patient Dosing in P-III Trial of Ivonescimab for the Treatment of Non-Squamous Non-Small Cell Lung Cancer

January 31, 2022

Genentech’s Vabysmo Receives the US FDA’s Approval for the Treatment of AMD and DME

Genentech’s Vabysmo Receives the US FDA’s Approval for the Treatment of AMD and DME

January 31, 2022

Pfizer’s Lorviqua (lorlatinib) Receives EC’s Approval as a 1L Treatment for ALK-Positive Advanced Non-Small Cell Lung Cancer

Pfizer’s Lorviqua (lorlatinib) Receives EC’s Approval as a 1L Treatment for ALK-Positive Advanced Non-Small Cell Lung Cancer

January 31, 2022

Contact Us

First Floor, B 150, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us